Comparing Antipsychotic Medications in LBD Over Time

Description

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

Conditions

Parkinson's Disease Psychosis, Dementia With Lewy Bodies

Study Overview

Study Details

Study overview

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

A Pragmatic Randomized Trial Comparing Antipsychotics in Lewy Body Disease

Comparing Antipsychotic Medications in LBD Over Time

Condition
Parkinson's Disease Psychosis
Intervention / Treatment

-

Contacts and Locations

San Antonio

University Health System, San Antonio, Texas, United States, 78229

San Antonio

UT Health Science Center - San Antonio, San Antonio, Texas, United States, 78229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients seen in the neurology clinic at UT Health San Antonio
  • * Diagnosed with psychosis due to PD or DLB
  • * Requiring initiation of an antipsychotic medication
  • * Clinical equipoise between quetiapine and pimavanserin must exist
  • * The prescribing provider must be comfortable prescribing and managing both quetiapine and pimavanserin
  • * Medical contraindication to either medication
  • * Caregiver unavailable to complete NPI-Q
  • * Currently taking an antipsychotic medication
  • * Prescribing provider unwilling to manage either medication

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

The University of Texas Health Science Center at San Antonio,

Sarah Horn, MD, PRINCIPAL_INVESTIGATOR, University of Texas Health Science Center San Antonio

Study Record Dates

2026-02